OTHERS UPDATE ON PHASE 4 UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) CLINICAL TRIAL OF SARS-COV-2 VACCINE STUDY, A PROJECT UNDER THE JOINT VENTURE BETWEEN E-MO BIOLOGY INC. (EBI), A COMPANY INCORPORATED IN USA AND HWGB BIOTECH SDN BHD, A WHOLLY OWNED SUBSIDIARY OF HO WAH GENTING BERHAD
| HO WAH GENTING BERHAD |
| Type | Announcement |
| Subject | OTHERS |
| Description | UPDATE ON PHASE 4 UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) CLINICAL TRIAL OF SARS-COV-2 VACCINE STUDY, A PROJECT UNDER THE JOINT VENTURE BETWEEN E-MO BIOLOGY INC. (EBI), A COMPANY INCORPORATED IN USA AND HWGB BIOTECH SDN BHD, A WHOLLY OWNED SUBSIDIARY OF HO WAH GENTING BERHAD |
|
Unless otherwise defined, the abbreviations and definitions used in the announcements dated 14 August 2020, 28 August 2020, 5 October 2020, 28 October 2020, 22 December 2020, 24 December 2020, 25 January 2021 and 21 June 2021 shall apply herein.
The Board of Directors of Ho Wah Genting Berhad (“HWGB” or “Company”) wishes to announce that EBI had on even date informed the Company that, upon advise from FDA, EBI had on 22 June 2021 submitted its report on the total 300 subjects assessed in relation to immune responses for the prevention of COVID-19 following a booster dose of inactivated poliovirus (IPV) vaccine in adults to the FDA under the Emergency Use Authorisation (EUA).
Please refer to https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization for more information on the EUA.
HWGB will update on the on-going progress of the aforesaid submission accordingly.
This announcement is dated 24 June 2021. |
|
Announcement Info
| Company Name | HO WAH GENTING BERHAD |
| Stock Name | HWGB |
| Date Announced | 24 Jun 2021 |
| Category | General Announcement for PLC |
| Reference Number | GA1-24062021-00107 |